Education
About Us
Working with TipRanks
Follow Us
Neuehealth Inc (NEUE)
:NEUE
Top Page
NeueHealth Inc
(NEUE)
Select Model
Select Model
Rating:49Neutral
Price Target:
$6.50
The overall stock score of 49 reflects significant financial challenges, with negative profitability and a weak balance sheet being the most impactful factors. Despite positive sentiment from the earnings call and strategic growth initiatives, the company's valuation and technical indicators suggest caution.
NeueHealth Inc (NEUE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)N/A
Revenue Growth-13.83%
EPS Growth87.09%
CountryUS
EmployeesN/A
SectorN/A
Sector StrengthN/A
IndustryN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NeueHealth Inc Business Overview & Revenue Model
Company DescriptionNeueHealth Inc (NEUE) is a healthcare technology company focused on transforming the way healthcare is delivered and managed. Operating within the digital health and telemedicine sectors, NeueHealth specializes in providing innovative solutions that enhance patient engagement, streamline healthcare operations, and improve overall health outcomes. The company offers a suite of products and services, including a digital health platform for remote patient monitoring, telehealth services, and data analytics tools that support healthcare providers in making informed decisions.
How the Company Makes MoneyNeueHealth generates revenue through multiple streams, including subscription fees from healthcare providers for access to its digital health platform, transaction fees from telehealth consultations, and licensing fees for its data analytics tools. Additionally, the company may engage in strategic partnerships with healthcare organizations, insurance companies, and technology firms to expand its service offerings and reach. These collaborations can lead to revenue-sharing agreements, further enhancing its income potential. The increasing demand for telehealth services and digital health solutions, accelerated by the COVID-19 pandemic, has significantly contributed to NeueHealth's growth and revenue generation.
NeueHealth Inc Earnings Call Summary
Earnings Call Date:Aug 07, 2025
(Q2-2025)
| Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong positive sentiment, highlighted by significant growth in consumer numbers, adjusted EBITDA profitability, and strategic expansions and collaborations. Despite a slight decrease in revenue, the company's advancements in their care model and data analytics platform indicate a positive trajectory.Q2-2025 Updates
Positive Updates
Adjusted EBITDA Profitability
NeueHealth achieved adjusted EBITDA profitability of $19 million in the second quarter, contributing to a total of $32.5 million for the first half of the year.
Consumer Growth
The company served 694,000 consumers in the second quarter, marking a 45% increase compared to the same period last year.
ACA Marketplace Performance
Served 485,000 ACA Marketplace consumers with differentiated results and improved medical loss ratio performance.
Collaborations and Expansions
NeueHealth began operating clinics inside Walgreens locations in Florida, expanding access to care with services including primary care and dermatology.
Medicaid and Provider Enablement
Served 144,000 Medicaid consumers with a strong focus on performance-based arrangements and partnerships with provider groups.
NeuePulse Platform Development
Advancement of NeuePulse platform integrating population health tools and care delivery solutions, aiming to align financing and care delivery.
Negative Updates
Revenue Decrease
Consolidated revenue for the second quarter was $209.1 million, slightly lower than the prior year due to a shift in membership mix.
Company Guidance
During the Second Quarter 2025 Earnings Call, NeueHealth reported a robust performance with significant metrics highlighting their success. The company achieved an adjusted EBITDA of $19 million for the quarter, contributing to a total of $32.5 million for the first half of the year. Revenue for the quarter stood at $209.1 million, driven by serving 694,000 consumers—a remarkable 45% increase compared to the previous year. The ACA Marketplace saw 485,000 consumers, while the senior care business served 65,000 consumers across Medicare Advantage, ACO REACH, and MSSP. Medicaid consumer numbers reached 144,000, with a focus on provider enablement. NeueHealth's innovative NeuePulse platform is expected to streamline care delivery further. The company ended the quarter with $234.4 million in total cash and investments, with $145.5 million in nonregulated cash and short-term investments. Overall, the call underscored NeueHealth's strategic growth and commitment to value-based, consumer-centric care.NeueHealth Inc Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
20
Very Negative
Cash Flow
25
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
NeueHealth Inc Technical Analysis
Positive
―
Price Trends
6.70
Positive
6.77
Negative
6.76
Negative
Market Momentum
0.01
Negative
52.93
Neutral
58.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEUE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 6.72, equal to the 50-day MA of 6.70, and equal to the 200-day MA of 6.76, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 52.93 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NEUE.
NeueHealth Inc Peers Comparison
UnderperformOutperform
Sector (―)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― |
* Sector Average
Performance Comparison
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.